CA3197056A1 - Combination therapy for treating cancer - Google Patents
Combination therapy for treating cancerInfo
- Publication number
- CA3197056A1 CA3197056A1 CA3197056A CA3197056A CA3197056A1 CA 3197056 A1 CA3197056 A1 CA 3197056A1 CA 3197056 A CA3197056 A CA 3197056A CA 3197056 A CA3197056 A CA 3197056A CA 3197056 A1 CA3197056 A1 CA 3197056A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- azd5305
- pharmaceutically acceptable
- acceptable salt
- carboplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089195P | 2020-10-08 | 2020-10-08 | |
| US63/089,195 | 2020-10-08 | ||
| PCT/EP2021/077703 WO2022074124A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3197056A1 true CA3197056A1 (en) | 2022-04-14 |
Family
ID=78293953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3197056A Pending CA3197056A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230372333A1 (https=) |
| EP (1) | EP4225297B1 (https=) |
| JP (1) | JP7818585B2 (https=) |
| KR (1) | KR20230083291A (https=) |
| CN (1) | CN116194110B (https=) |
| AU (1) | AU2021356123B2 (https=) |
| BR (1) | BR112023005160A2 (https=) |
| CA (1) | CA3197056A1 (https=) |
| DK (1) | DK4225297T3 (https=) |
| ES (1) | ES3005507T3 (https=) |
| FI (1) | FI4225297T3 (https=) |
| HU (1) | HUE069249T2 (https=) |
| IL (1) | IL301687A (https=) |
| MX (1) | MX2023004156A (https=) |
| PL (1) | PL4225297T3 (https=) |
| PT (1) | PT4225297T (https=) |
| TW (1) | TW202228693A (https=) |
| WO (1) | WO2022074124A1 (https=) |
| ZA (1) | ZA202304965B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| US20230250428A1 (en) * | 2022-02-07 | 2023-08-10 | Alliance Of Cardiovascular Researchers | Method and composition for early detection of malignancies |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| CN118973572A (zh) * | 2022-04-07 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN121464135A (zh) * | 2023-07-07 | 2026-02-03 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
-
2021
- 2021-10-06 TW TW110137116A patent/TW202228693A/zh unknown
- 2021-10-07 ES ES21794474T patent/ES3005507T3/es active Active
- 2021-10-07 DK DK21794474.3T patent/DK4225297T3/da active
- 2021-10-07 US US18/248,108 patent/US20230372333A1/en active Pending
- 2021-10-07 EP EP21794474.3A patent/EP4225297B1/en active Active
- 2021-10-07 KR KR1020237013320A patent/KR20230083291A/ko active Pending
- 2021-10-07 CN CN202180065599.5A patent/CN116194110B/zh active Active
- 2021-10-07 WO PCT/EP2021/077703 patent/WO2022074124A1/en not_active Ceased
- 2021-10-07 PT PT217944743T patent/PT4225297T/pt unknown
- 2021-10-07 MX MX2023004156A patent/MX2023004156A/es unknown
- 2021-10-07 CA CA3197056A patent/CA3197056A1/en active Pending
- 2021-10-07 JP JP2023521357A patent/JP7818585B2/ja active Active
- 2021-10-07 BR BR112023005160A patent/BR112023005160A2/pt unknown
- 2021-10-07 AU AU2021356123A patent/AU2021356123B2/en active Active
- 2021-10-07 IL IL301687A patent/IL301687A/en unknown
- 2021-10-07 HU HUE21794474A patent/HUE069249T2/hu unknown
- 2021-10-07 FI FIEP21794474.3T patent/FI4225297T3/fi active
- 2021-10-07 PL PL21794474.3T patent/PL4225297T3/pl unknown
-
2023
- 2023-05-04 ZA ZA2023/04965A patent/ZA202304965B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202304965B (en) | 2024-09-25 |
| HUE069249T2 (hu) | 2025-02-28 |
| JP7818585B2 (ja) | 2026-02-20 |
| EP4225297A1 (en) | 2023-08-16 |
| BR112023005160A2 (pt) | 2023-04-18 |
| MX2023004156A (es) | 2023-05-03 |
| CN116194110B (zh) | 2025-06-17 |
| DK4225297T3 (da) | 2025-01-02 |
| ES3005507T3 (en) | 2025-03-14 |
| AU2021356123A1 (en) | 2023-06-08 |
| PL4225297T3 (pl) | 2025-03-17 |
| TW202228693A (zh) | 2022-08-01 |
| KR20230083291A (ko) | 2023-06-09 |
| PT4225297T (pt) | 2024-12-30 |
| AU2021356123B2 (en) | 2025-01-09 |
| WO2022074124A1 (en) | 2022-04-14 |
| FI4225297T3 (fi) | 2024-12-10 |
| IL301687A (en) | 2023-05-01 |
| EP4225297B1 (en) | 2024-10-23 |
| JP2023546362A (ja) | 2023-11-02 |
| CN116194110A (zh) | 2023-05-30 |
| US20230372333A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021356123B2 (en) | Combination therapy for treating cancer | |
| US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| CN107949557B (zh) | 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类 | |
| EA032530B1 (ru) | 4h-пирроло[3,2-c]пиридин-4-оновые производные | |
| TW202131930A (zh) | 抗癌核荷爾蒙受體標靶化合物 | |
| CN116348115A (zh) | 抗体-药物缀合物和parp1选择性抑制剂的组合 | |
| EP4452256B1 (en) | Methods of treating brain tumours and neuroblastomas | |
| CN111527076A (zh) | 共晶体、其药物组合物以及涉及其的治疗方法 | |
| KR102468480B1 (ko) | 신규한 화합물 및 이를 포함하는 항암 활성 증진용 약학 조성물 | |
| EP3233839B1 (en) | Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors | |
| HK40099137A (en) | Combination therapy for treating cancer | |
| HK40099137B (en) | Combination therapy for treating cancer | |
| EA049465B1 (ru) | Комбинированная терапия для лечения рака | |
| CN103328461A (zh) | 使用渥曼青霉素类似物的结晶形式的组合物及方法 | |
| CN117693517A (zh) | 用于靶向治疗肾癌的新型化合物和组合物 | |
| CN120904168A (zh) | 第四代egfr抑制剂、及其制备方法和在药学上的应用 | |
| BR122024006404A2 (pt) | Compostos inibidores de tirosina e de cdc2 específica de treonina cinase e composição farmacêutica compreendendo os mesmos | |
| JP2025503215A (ja) | Ｎｔｓｒ１標的化放射性医薬品およびｄｎａ損傷応答阻害剤併用療法 | |
| AU2023307933A1 (en) | Enantiomer of azopodophyllotoxin derivative su056 | |
| CN121969614A (zh) | Idh1抑制剂的共晶、其制备方法、其药物组合物及涉及其的治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251002 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251204 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251223 |